Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

2019-12-31
Price :
Published : Dec-2019
No. of Pages : 38

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms. The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017). Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for COPD was based on symptoms and the results of spirometry testing. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. GlobalData epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in GlobalData’s forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope

– The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ?35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
– The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global COPD market.
– Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
– Understand magnitude of COPD population by severity at diagnosis.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Telehealth Market by Component Software & Services (RPM, RTM), Application (Teleradiology, telestroke, teleICU), Hardware (Glucose Meters), End-User (Provider, Payer, Patient), Delivery Mode (On-Premise, Cloud) Trends & Global Forecast to 2025

“The telehealth market is projected to grow at a CAGR of 16.9% during the forecast period (2020–2025).” The global telehealth market is projected to reach USD 55.6 billion by 2025 from USD 25.5 billion in 2020, at a CAGR of 16.9 % during the forecast period. The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, and government support and raising awareness. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. “The software & services segment will grow at the highest rate during the forecast period.” Base......
$4950

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

“The global biosimilars  market size is projected to register a CAGR of 24.7% during the forecast period.” The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market. “The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.” The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept......
$5650

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H1, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Post Operative Nausea And Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Post Operative Nausea And Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020" provides an overview of Seasonal Allergic Rhinitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Seasonal Allergic Rhinitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Cirrhosis Global Clinical Trials Review, H1, 2020

Cirrhosis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H1, 2020" provides an overview of Cirrhosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy